PNPLA3 gene polymorphism and overall and cardiovascular mortality in the United States.
Adult
Alleles
Cardiovascular Diseases
/ epidemiology
Comorbidity
Female
Follow-Up Studies
Genetic Association Studies
Genetic Predisposition to Disease
/ genetics
Genotype
Humans
Lipase
/ genetics
Male
Membrane Proteins
/ genetics
Non-alcoholic Fatty Liver Disease
/ mortality
Polymorphism, Genetic
/ genetics
Risk Factors
Time Factors
United States
/ epidemiology
NHANES
PNPLA3
mortality
nonalcoholic fatty liver disease
nonalcoholic steatohepatitis
Journal
Journal of gastroenterology and hepatology
ISSN: 1440-1746
Titre abrégé: J Gastroenterol Hepatol
Pays: Australia
ID NLM: 8607909
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
13
07
2019
revised:
04
03
2020
accepted:
23
03
2020
pubmed:
29
3
2020
medline:
24
11
2020
entrez:
29
3
2020
Statut:
ppublish
Résumé
The association between palatin-like phospholipase domain-containing 3 (PNPLA3) I148M (rs738409) polymorphism and mortality is not well understood. We investigated the impact of PNPLA3 I148M (rs738409) polymorphism on overall and cardiovascular mortality based on the presence of nonalcoholic fatty liver disease (NAFLD). The third National Health and Nutrition Examination Survey (NHANES) from 1991 to 1994 and National Health and Nutrition Examination Survey III-linked mortality data through 31 December 2015 were utilized in this study. Of 4814 participants, 50.7% were homozygous for the C-allele and 12.6% were homozygous for the G-allele. During a follow up of 20 years, there were a total of 1255 deaths, 422 attributed to cardiovascular disease. There was a significant association with overall mortality among those with the PNPLA3 I148M (rs738409) GG genotype (hazard ratio [HR] 1.34, 95% confidence interval [CI] 1.02-1.77) or G-allele (HR 1.22, 95% CI 1.09-1.36) in the general population. NAFLD with homozygous PNPLA3 I148M (rs738409) GG genotype had higher overall mortality after adjusting for multiple metabolic risk factors (HR 1.45, 95% CI 1.01-2.08). The PNPLA3 I148M (rs738409) G-allele had a tendency of increased cardiovascular mortality in the total population. This association was not noted in those with NAFLD. The homozygous PNPLA3 I148M (rs738409) GG genotype showed an increase in overall mortality in the general population and NAFLD independent of multiple metabolic risk factors.
Sections du résumé
BACKGROUND AND AIM
OBJECTIVE
The association between palatin-like phospholipase domain-containing 3 (PNPLA3) I148M (rs738409) polymorphism and mortality is not well understood. We investigated the impact of PNPLA3 I148M (rs738409) polymorphism on overall and cardiovascular mortality based on the presence of nonalcoholic fatty liver disease (NAFLD).
METHODS
METHODS
The third National Health and Nutrition Examination Survey (NHANES) from 1991 to 1994 and National Health and Nutrition Examination Survey III-linked mortality data through 31 December 2015 were utilized in this study.
RESULTS
RESULTS
Of 4814 participants, 50.7% were homozygous for the C-allele and 12.6% were homozygous for the G-allele. During a follow up of 20 years, there were a total of 1255 deaths, 422 attributed to cardiovascular disease. There was a significant association with overall mortality among those with the PNPLA3 I148M (rs738409) GG genotype (hazard ratio [HR] 1.34, 95% confidence interval [CI] 1.02-1.77) or G-allele (HR 1.22, 95% CI 1.09-1.36) in the general population. NAFLD with homozygous PNPLA3 I148M (rs738409) GG genotype had higher overall mortality after adjusting for multiple metabolic risk factors (HR 1.45, 95% CI 1.01-2.08). The PNPLA3 I148M (rs738409) G-allele had a tendency of increased cardiovascular mortality in the total population. This association was not noted in those with NAFLD.
CONCLUSIONS
CONCLUSIONS
The homozygous PNPLA3 I148M (rs738409) GG genotype showed an increase in overall mortality in the general population and NAFLD independent of multiple metabolic risk factors.
Substances chimiques
Membrane Proteins
0
Lipase
EC 3.1.1.3
adiponutrin, human
EC 3.1.1.3
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1789-1794Subventions
Organisme : E. Donnall Thomas Resident Research Program, Bassett Research Institute, Cooperstown, New York, USA
Organisme : E. Donnall Thomas Resident Research Program
Informations de copyright
© 2020 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Références
Perumpail BJ, Khan MA, Yoo ER, Cholankeril G, Kim D, Ahmed A. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World J. Gastroenterol. 2017; 23: 8263-8276.
Mandorfer M, Scheiner B, Stattermayer AF et al. Impact of patatin-like phospholipase domain containing 3 rs738409 G/G genotype on hepatic decompensation and mortality in patients with portal hypertension. Aliment. Pharmacol. Ther. 2018; 48: 451-459.
Romeo S, Kozlitina J, Xing C et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 2008; 40: 1461-1465.
Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 2011; 53: 1883-1894.
Meffert PJ, Repp KD, Volzke H et al. The PNPLA3 SNP rs738409:G allele is associated with increased liver disease-associated mortality but reduced overall mortality in a population-based cohort. J. Hepatol. 2018; 68: 858-860.
Simons N, Isaacs A, Koek GH, Kuc S, Schaper NC, Brouwers M. PNPLA3, TM6SF2, and MBOAT7 genotypes and coronary artery disease. Gastroenterology 2017; 152: 912-913.
McQuillan GM, McLean JE, Chiappa M, Corporation H, Lukacs SL. National Health and Nutrition Examination Survey biospecimen program: NHANES III (1988-1994) and NHANES 1999-2014. National Center for Health Statistics. Vital Health Stat 2 2015; 170: 1-14.
Goran MI, Walker R, Le KA et al. Effects of PNPLA3 on liver fat and metabolic profile in Hispanic children and adolescents. Diabetes 2010; 59: 3127-3130.
Martinez LA, Larrieta E, Kershenobich D, Torre A. The expression of PNPLA3 polymorphism could be the key for severe liver disease in NAFLD in Hispanic population. Ann. Hepatol. 2017; 16: 909-915.
Atkinson SR, Way MJ, McQuillin A, Morgan MY, Thursz MR. Homozygosity for rs738409:G in PNPLA3 is associated with increased mortality following an episode of severe alcoholic hepatitis. J. Hepatol. 2017; 67: 120-127.
Grimaudo S, Pipitone RM, Pennisi G et al. Association between PNPLA3 rs738409 C>G variant and liver-related outcomes in patients with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 2020; 18: 935-944 e3.
Pingitore P, Pirazzi C, Mancina RM et al. Recombinant PNPLA3 protein shows triglyceride hydrolase activity and its I148M mutation results in loss of function. Biochim. Biophys. Acta 2014; 1841: 574-580.
Pingitore P, Romeo S. The role of PNPLA3 in health and disease. Biochim Biophys Acta Mol Cell Biol Lipids 2019; 1864: 900-906.
Kim D, Kim WR, Kim HJ, Therneau TM. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology 2013; 57: 1357-1365.
Kim D, Li AA, Gadiparthi C et al. Changing trends in etiology-based annual mortality from chronic liver disease, from 2007 through 2016. Gastroenterology 2018; 155: 1154-1163 e3.
Sliz E, Sebert S, Wurtz P et al. NAFLD risk alleles in PNPLA3, TM6SF2, GCKR and LYPLAL1 show divergent metabolic effects. Hum. Mol. Genet. 2018; 27: 2214-2223.
Unalp-Arida A, Ruhl CE. PNPLA3 I148M and liver fat and fibrosis scores predict liver disease mortality in the United States population. Hepatology 2019; 71: 820-834.
Kantartzis K, Peter A, Machicao F et al. Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene. Diabetes 2009; 58: 2616-2623.
Ballestri S, Nascimbeni F, Baldelli E et al. Ultrasonographic fatty liver indicator detects mild steatosis and correlates with metabolic/histological parameters in various liver diseases. Metab. Clin. Experiment. 2017; 72: 57-65.